Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29328061 | 0.96 | CHRM5 (0.49) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL26741475 | 0.91 | CHRM5 (0.51) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL26742907 | 0.88 | CHRM5 (0.47) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL26742799 | 0.88 | HTT (0.46) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL29322471 | 0.84 | CHRM5 (0.48) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL26741473 | 0.84 | CHRM5 (0.48) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL26744518 | 0.84 | CHRM5 (0.50) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL26741589 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TDP1HTTSIGMAR1HTR4 | |
| SCHEMBL29328227 | 0.82 | CHRM5 (0.43) | CHRM5CHRM3ALDH1A1TDP1HTT | |
| SCHEMBL26741494 | 0.81 | CHRM5 (0.50) | CHRM5CHRM3ALDH1A1TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | CHRM5 4872/4885CHRM3 4860/4885ALDH1A1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.